Comparing treatment intensities for less fit adults with AML
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have acute myeloid leukemia or a similar high-grade bone marrow cancer (not a rare type called APL).
- You have at least one health issue that makes you less fit for strong chemo, like being less active (ECOG 2-3), having heart problems, kidney issues, or lung problems.
- Your heart function (ejection fraction) is at least 40%, checked recently.
- You have acceptable liver and kidney function (certain test results within limits).
- If female and able to have children, you agree to use birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of chemotherapy (FLAG-Ida) followed by low-dose total body radiation and a stem cell transplant from a donor. It is for people age 60 and older with newly diagnosed high-risk blood cancers, aiming to improve outcomes with a less intense transplant preparative regimen.
This trial tests a strong chemotherapy and radiation combo followed by a donor stem cell transplant for people with aggressive blood cancers (like AML or MDS) that haven't responded to earlier treatments or came back. It aims to help prevent the cancer from returning.
This trial compares two types of chemotherapy for people with acute myeloid leukemia (AML) that came back or did not get better after initial treatment. Your doctor will help decide if you can join, and you will be randomly assigned to either a lower-intensity or a higher-intensity treatment plan.
This trial aims to help doctors choose the best treatment for older adults with acute myeloid leukemia (AML) by using a special health assessment that looks at your overall well-being. The study will compare different treatment options based on this assessment, with the goal of improving outcomes and quality of life.
This trial compares standard chemotherapy with newer drug combinations (CPX-351 and gilteritinib) for children and young adults with acute myeloid leukemia (AML), a type of blood cancer. It aims to find which treatment works better and who might benefit from targeted therapy based on specific genetic changes (FLT3 mutations).
This study screens people with newly suspected acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) to see which treatment approach fits best—either a specific study treatment or standard care. It may help by directing you to the right option and by sharing your blood/bone marrow samples for research.
Hear when a new Acute Leukemia of Ambiguous Lineage trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.